226 related articles for article (PubMed ID: 32146584)
1. Primary pulmonary lymphoepithelioma-like carcinoma.
Fan Y; Li C; Qin J; Lu H
Med Oncol; 2020 Mar; 37(3):20. PubMed ID: 32146584
[TBL] [Abstract][Full Text] [Related]
2. [Clinical Analysis of Primary Pulmonary Lymphoepithelioma-like Carcinoma in 8 Patients].
Zhao H; Chen J
Zhongguo Fei Ai Za Zhi; 2020 Mar; 23(3):168-175. PubMed ID: 32209185
[TBL] [Abstract][Full Text] [Related]
3. Molecular and Clinical Characteristics of Primary Pulmonary Lymphoepithelioma-Like Carcinoma.
Fan Y; Shan Q; Gong J; Qin J; Lu H
Front Mol Biosci; 2021; 8():736940. PubMed ID: 34760925
[No Abstract] [Full Text] [Related]
4. Clinicopathological characteristics and cancer-specific prognosis of primary pulmonary lymphoepithelioma-like carcinoma: a population study of the US SEER database and a Chinese hospital.
Zhang Q; Dai Y; Jin L; Shi S; Liu C; Rong R; Sun W; Dai S; Kong H; Xie W
Front Oncol; 2023; 13():1103169. PubMed ID: 37274245
[TBL] [Abstract][Full Text] [Related]
5. The clinicopathological features and prognosis of primary pulmonary lymphoepithelioma-like carcinoma: A systematic review and meta-analysis.
Tang L; Chen N; He W; Zhou J; Zhang J; Lin Z; Wang Z; Hao J; Lin F
PLoS One; 2020; 15(10):e0240729. PubMed ID: 33064745
[TBL] [Abstract][Full Text] [Related]
6. Immune Checkpoint Blockade Therapy May Be a Feasible Option for Primary Pulmonary Lymphoepithelioma-like Carcinoma.
Wu Z; Xian X; Wang K; Cheng D; Li W; Chen B
Front Oncol; 2021; 11():626566. PubMed ID: 33981599
[TBL] [Abstract][Full Text] [Related]
7. Long-term survival of locally advanced stage III non-small cell lung cancer patients treated with chemoradiotherapy and perspectives for the treatment with immunotherapy.
Vrankar M; Stanic K
Radiol Oncol; 2018 Feb; 52(3):281-288. PubMed ID: 30210037
[TBL] [Abstract][Full Text] [Related]
8. Primary pulmonary lymphoepithelioma-like carcinoma: A case report of pathological complete response (pCR) by neoadjuvant treatment.
Zhang L; Hao T; Wei Y; Dong M; Xiong Y
Medicine (Baltimore); 2021 Mar; 100(11):e24987. PubMed ID: 33725970
[TBL] [Abstract][Full Text] [Related]
9. Programmed cell death ligand 1 expression in cytologic and surgical non-small cell lung carcinoma specimens from a single institution: Association with clinicopathologic features and molecular alterations.
Mei P; Shilo K; Wei L; Shen R; Tonkovich D; Li Z
Cancer Cytopathol; 2019 Jul; 127(7):447-457. PubMed ID: 31025831
[TBL] [Abstract][Full Text] [Related]
10. Analysis of clinical features, treatment, and prognosis of primary Xlymphoepithelioma-like carcinoma of the lung.
Hu HY; Long L; Dai SA; Yan GQ; Huang Y; He J
Eur Rev Med Pharmacol Sci; 2022 Dec; 26(24):9416-9425. PubMed ID: 36591850
[TBL] [Abstract][Full Text] [Related]
11. Anti-angiogenic therapy for advanced primary pulmonary lymphoepithelioma-like carcinoma: a retrospective multicenter study.
Bao H; Ma LZ; Zhao C; Yu M; Zhang B; Zhang J; Peng G; Lin X; Fang Y; Bao H; Ma S
J Cancer Res Clin Oncol; 2023 Mar; 149(3):1185-1193. PubMed ID: 35377040
[TBL] [Abstract][Full Text] [Related]
12. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
13. Dynamic changes in PD-L1 expression and CD8
Choe EA; Cha YJ; Kim JH; Pyo KH; Hong MH; Park SY; Shim HS; Jung I; Lee CY; Cho BC; Kim HR
Lung Cancer; 2019 Oct; 136():30-36. PubMed ID: 31421259
[TBL] [Abstract][Full Text] [Related]
14. Primary pulmonary lymphoepithelioma-like carcinoma: fifty-two patients with long-term follow-up.
Liang Y; Wang L; Zhu Y; Lin Y; Liu H; Rao H; Xu G; Rong T
Cancer; 2012 Oct; 118(19):4748-58. PubMed ID: 22359203
[TBL] [Abstract][Full Text] [Related]
15. Prior or concurrent radiotherapy and nivolumab immunotherapy in non-small cell lung cancer.
Ratnayake G; Shanker M; Roberts K; Mason R; Hughes BGM; Lwin Z; Jain V; O'Byrne K; Lehman M; Chua B
Asia Pac J Clin Oncol; 2020 Feb; 16(1):56-62. PubMed ID: 31721446
[TBL] [Abstract][Full Text] [Related]
16. Tumor size does not predict pathological complete response rates after pre-operative chemoradiotherapy for non-small cell lung cancer.
Vos CG; Dahele M; Dickhoff C; Senan S; Thunnissen E; Hartemink KJ
Acta Oncol; 2013 Apr; 52(3):676-8. PubMed ID: 23098694
[No Abstract] [Full Text] [Related]
17. Feasibility and efficacy of salvage lung resection after definitive chemoradiation therapy for Stage III non-small-cell lung cancer.
Shimada Y; Suzuki K; Okada M; Nakayama H; Ito H; Mitsudomi T; Saji H; Takamochi K; Kudo Y; Hattori A; Mimae T; Aokage K; Nishii T; Tsuboi M; Ikeda N
Interact Cardiovasc Thorac Surg; 2016 Dec; 23(6):895-901. PubMed ID: 27543652
[TBL] [Abstract][Full Text] [Related]
18. Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response.
Machtay M; Lee JH; Stevenson JP; Shrager JB; Algazy KM; Treat J; Kaiser LR
J Thorac Cardiovasc Surg; 2004 Jan; 127(1):108-13. PubMed ID: 14752420
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 expression can be regarded as prognostic factor for survival of non-small cell lung cancer patients after chemoradiotherapy.
Vrankar M; Zwitter M; Kern I; Stanic K
Neoplasma; 2018; 65(1):140-146. PubMed ID: 29322798
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review.
Brody R; Zhang Y; Ballas M; Siddiqui MK; Gupta P; Barker C; Midha A; Walker J
Lung Cancer; 2017 Oct; 112():200-215. PubMed ID: 29191596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
